Sunho Biologics: No Share Capital Movement in March 2026; Public Float Fully Compliant

Bulletin Express04-09

Sunho Biologics, Inc. (SUNHO BIO-B) submitted its Monthly Return for the period ending 31 March 2026, confirming a stable capital structure and full compliance with Hong Kong Exchange listing requirements. The filing was lodged on 09 April 2026.

Authorised Share Capital • Remained at 200.00 million ordinary shares with a par value of USD 0.0005 each, equivalent to USD 0.10 million. No changes were recorded during the month.

Issued Shares • Outstanding ordinary shares stayed at 156.67 million. • The company held no treasury shares, and there were no share issuances, cancellations, or repurchases in March.

Public Float • Management affirmed adherence to the 25% minimum public-float threshold specified under Main Board Rule 13.32B.

Capital Instruments and Dilution Events • The return reported no outstanding or new share options, warrants, convertibles, or other equity-linked instruments.

Governance • The document was signed by Chairman and Executive Director Zhang Feng, confirming the accuracy of the disclosed information.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1167143825?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 17:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167143825","market":"us","top_or_hot":-1,"title":"Sunho Biologics: No Share Capital Movement in March 2026; Public Float Fully Compliant","media":"Bulletin Express","content":"<p>Sunho Biologics, Inc. (SUNHO BIO-B) submitted its Monthly Return for the period ending 31 March 2026, confirming a stable capital structure and full compliance with Hong Kong Exchange listing requirements. The filing was lodged on 09 April 2026.</p>\n<p>Authorised Share Capital  \n• Remained at 200.00 million ordinary shares with a par value of USD 0.0005 each, equivalent to USD 0.10 million. No changes were recorded during the month.</p>\n<p>Issued Shares  \n• Outstanding ordinary shares stayed at 156.67 million.  \n• The company held no treasury shares, and there were no share issuances, cancellations, or repurchases in March.</p>\n<p>Public Float  \n• Management affirmed adherence to the 25% minimum public-float threshold specified under Main Board Rule 13.32B.</p>\n<p>Capital Instruments and Dilution Events  \n• The return reported no outstanding or new share options, warrants, convertibles, or other equity-linked instruments.</p>\n<p>Governance  \n• The document was signed by Chairman and Executive Director Zhang Feng, confirming the accuracy of the disclosed information.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sunho Biologics: No Share Capital Movement in March 2026; Public Float Fully Compliant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSunho Biologics: No Share Capital Movement in March 2026; Public Float Fully Compliant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-09 17:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sunho Biologics, Inc. (SUNHO BIO-B) submitted its Monthly Return for the period ending 31 March 2026, confirming a stable capital structure and full compliance with Hong Kong Exchange listing requirements. The filing was lodged on 09 April 2026.</p>\n<p>Authorised Share Capital  \n• Remained at 200.00 million ordinary shares with a par value of USD 0.0005 each, equivalent to USD 0.10 million. No changes were recorded during the month.</p>\n<p>Issued Shares  \n• Outstanding ordinary shares stayed at 156.67 million.  \n• The company held no treasury shares, and there were no share issuances, cancellations, or repurchases in March.</p>\n<p>Public Float  \n• Management affirmed adherence to the 25% minimum public-float threshold specified under Main Board Rule 13.32B.</p>\n<p>Capital Instruments and Dilution Events  \n• The return reported no outstanding or new share options, warrants, convertibles, or other equity-linked instruments.</p>\n<p>Governance  \n• The document was signed by Chairman and Executive Director Zhang Feng, confirming the accuracy of the disclosed information.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02898","symbol_name":"盛禾生物-B","start_time":0,"source_url":"","article_id":"1167143825","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167143825","pubTimestamp":1775725386,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sunho Biologics, Inc. (SUNHO BIO-B) submitted its Monthly Return for the period ending 31 March 2026, confirming a stable capital structure and full compliance with Hong Kong Exchange listing...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02898":"盛禾生物-B"},"translate_title":"Sunho Biologics：2026年3月无股本变动；公众持股量完全合规","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02898":1},"content_text":"Sunho Biologics, Inc. (SUNHO BIO-B) submitted its Monthly Return for the period ending 31 March 2026, confirming a stable capital structure and full compliance with Hong Kong Exchange listing requirements. The filing was lodged on 09 April 2026.\nAuthorised Share Capital  \n• Remained at 200.00 million ordinary shares with a par value of USD 0.0005 each, equivalent to USD 0.10 million. No changes were recorded during the month.\nIssued Shares  \n• Outstanding ordinary shares stayed at 156.67 million.  \n• The company held no treasury shares, and there were no share issuances, cancellations, or repurchases in March.\nPublic Float  \n• Management affirmed adherence to the 25% minimum public-float threshold specified under Main Board Rule 13.32B.\nCapital Instruments and Dilution Events  \n• The return reported no outstanding or new share options, warrants, convertibles, or other equity-linked instruments.\nGovernance  \n• The document was signed by Chairman and Executive Director Zhang Feng, confirming the accuracy of the disclosed information.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1167143825","isCrawlerRequest":true}